Rachel Koch, MD, John G. Meara, MD, DMD, MBA, and Anji E. Wall, MD, PhD
Single-procedure interventions with minimal follow-up and clear quality-of-life gain are well suited for surgical mission trips. But not all risks and benefits are easily assessed.
AMA J Ethics. 2019;21(9):E729-734. doi:
10.1001/amajethics.2019.729.
How do we determine what a fair price for a life-saving prescription medication should be? This month, we discuss what is means for a price to be “fair” and explore the current legal and economic landscape of prescription drug pricing in the US.
Global health outreach programs can risk benefitting students from resource-rich areas of the world more than the patients in resource-poor areas of the world. This month’s episode of Ethics Talk explores an alternative to academic health center-based health outreach programs.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Ruth M. Farrell, MD, MA, Marsha Michie, PhD, Christopher T. Scott, PhD, Rebecca Flyckt, MD, and Mary LaPlante, MD
One reason for neglect of women’s health as patients and subjects has been restrictions on uterine transfer of modified human embryos, a boundary that has now been crossed.
AMA J Ethics. 2019;21(12):E1071-1078. doi:
10.1001/amajethics.2019.1071.
Family presence during resuscitation of a child remains controversial and disagreement persists about whether and when potential benefits outweigh risks.
AMA J Ethics. 2018;20(5):507-512. doi:
10.1001/journalofethics.2018.20.5.sect1-1805.